- Home
- ZTR vs ARCT Comparison
ZTR vs ARCT Comparison
Compare ZTR & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- ARCT
- Stock Information
- Founded
- ZTR 1988
- ARCT 2013
- Country
- ZTR Australia
- ARCT United States
- Employees
- ZTR N/A
- ARCT N/A
- Industry
- ZTR Investment Managers
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- ZTR Finance
- ARCT Health Care
- Exchange
- ZTR Nasdaq
- ARCT Nasdaq
- Market Cap
- ZTR 338.8M
- ARCT 298.3M
- IPO Year
- ZTR N/A
- ARCT N/A
- Fundamental
- Price
- ZTR $6.17
- ARCT $12.53
- Analyst Decision
- ZTR
- ARCT Strong Buy
- Analyst Count
- ZTR 0
- ARCT 8
- Target Price
- ZTR N/A
- ARCT $52.33
- AVG Volume (30 Days)
- ZTR 219.4K
- ARCT 450.8K
- Earning Date
- ZTR 01-01-0001
- ARCT 05-12-2025
- Dividend Yield
- ZTR 12.09%
- ARCT N/A
- EPS Growth
- ZTR N/A
- ARCT N/A
- EPS
- ZTR N/A
- ARCT N/A
- Revenue
- ZTR N/A
- ARCT $143,680,000.00
- Revenue This Year
- ZTR N/A
- ARCT N/A
- Revenue Next Year
- ZTR N/A
- ARCT $42.36
- P/E Ratio
- ZTR N/A
- ARCT N/A
- Revenue Growth
- ZTR N/A
- ARCT 15.38
- 52 Week Low
- ZTR $4.50
- ARCT $8.04
- 52 Week High
- ZTR $6.60
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- ZTR 60.53
- ARCT 54.31
- Support Level
- ZTR $6.06
- ARCT $11.51
- Resistance Level
- ZTR $6.23
- ARCT $13.00
- Average True Range (ATR)
- ZTR 0.09
- ARCT 0.98
- MACD
- ZTR -0.00
- ARCT 0.08
- Stochastic Oscillator
- ZTR 80.65
- ARCT 57.74
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.